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Purpose: Although important progress has been made in understanding age-related macular 
degeneration (AMD), management of the disease continues to be a challenge. AMD research 
has led to a widening of available treatment options and improved prognostic perspectives. This 
essay reviews these treatment options.
Design: Interpretative essay.
Methods: Literature review and interpretation.
Results: Current treatments to preserve vision in patients with non-exudative AMD include 
antioxidant vitamins and mineral supplementations. Exudative AMD is currently most often 
treated monthly with anti-VEGF intra-vitreal injections. However, investigators are beginning to 
experiment with combination therapy and surgical approaches in an attempt to limit the number 
of treatment and reduce the ﬁ  nancial burden on the health care system.
Conclusion: By better understanding the basis and pathogenesis of AMD, newer therapies will 
continue to be developed that target speciﬁ  c pathways in patients with AMD, with the hoped 
for outcome of better management of the disease and improved visual acuity.
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Introduction
In industrialized nations, age-related macular degeneration (AMD) is the leading 
cause of vision loss and blindness in people over age 65.1–4 As the disease affects the 
central regions of the retina and choroid, central visual loss can ensue. Approximately 
30% of adults aged 75 or older have some signs of maculopathy, and 6% to 8% of 
these individuals are afﬂ  icted with the advanced stages of AMD. Due to increased life 
expectancy and current demographics, the prevalence of AMD is expected to double 
by the year 2020.5–7
There are two major clinical presentations of AMD: non-exudative or atrophic 
AMD, which is characterized by the degeneration of choriocapillaries, retinal pig-
ment epithelium (RPE) and neurosensory retina; and neovascular or exudative AMD, 
which is characterized by the development of serous RPE (retinal pigment epithelium) 
detachments and/or new choroidal vessels that can lead to bleeding, exudation, and 
eventual scar formation. Although the exudative form of AMD only accounts for 10% 
to 20% of the overall incidence of AMD, it is responsible for over 90% of cases with 
severe visual loss.8,9
The management of either type of AMD continues to be a challenge for patients, 
ophthalmologists, and the healthcare system. The primary purpose of AMD disease 
management is to minimize visual loss and the related physical and emotional 
impairment, and to optimize vision-related quality of life. Recently, the important 
progress made in the comprehension and knowledge about basic pathologic mechanisms 
in both types of AMD has led to novel developments in therapeutic strategies resulting 
in a widening of available treatment options and improved prognostic perspectives.10 Clinical Ophthalmology 2009:3 156
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Treatment options span a broad range of therapeutic 
approaches, including thermal laser photocoagulation, 
surgical approaches (excision, displacement, or transplan-
tation), and new treatments targeting the CNV component 
and its pathogenic cascade, such as verteporﬁ  n with photo-
dynamic therapy (vPDT) and more recently anti-vascular 
endothelial growth factor (VEGF) therapies. Because of 
relatively revolutionary efﬁ  cacy results using anti-VEGF 
therapy, we can now, for the ﬁ  rst time, anticipate that over a 
quarter of our patients with exudative AMD will show visual 
improvement. Emerging strategies such as RNA interference, 
gene therapy, and new treatment targets such as integrin 
inhibitors and complement modifying agents great promise 
and are under study. This review will focus on summarizing 
the actual therapeutic options in the clinical management of 
the different forms of AMD and provide an overview about 
therapeutic perspectives.
Current treatment in clinical use
Prevention in intermediate 
and advanced AMD
It is well recognized that oxidative stress likely contrib-
utes to the pathogenesis of AMD. The retina’s defenses 
to such processes include glutathione (GSH) peroxides, 
catalases, and antioxidant nutrients such as vitamins E 
and C and carotenoids. With this understanding, it has been 
hypothesized that people with low levels of these antioxi-
dants may be more prone to oxidative damage in the retina, 
which may ultimately lead to AMD. It is reasonable to 
speculate that consuming higher levels of these antioxidants 
may protect an individual from developing AMD. This was 
hypothesized and proven by the Age-Related Eye Disease 
Study Group who showed that antioxidants and zinc supple-
ments could reduce the risk of progression in some forms 
of AMD. More speciﬁ  cally, early AMD (AREDS category 
2), characterized by small and intermediate drusen with no 
or minimal pigment epithelial abnormalities in the macula, 
progressed to advanced AMD in only 1.3% of cases at 5 
years.11 Alternatively, intermediate AMD (AREDS cat-
egory 3), charaterized by extensive medium-sized drusen 
(125 μm in diameter) in one or both eyes, progressed to 
advanced AMD in 18% of cases. No evidence was found 
to support the use of antioxidant vitamins and mineral 
supplementation in early AMD. Conversely, patients with 
either intermediate or advanced AMD (in one eye) beneﬁ  ted 
from a combination of antioxidant vitamin and mineral 
supplementation (AREDS formulation: vitamin C 500 mg, 
vitamin E 400 IU, beta-carotene 15 mg, zinc oxide 80 mg, 
and cupric oxide 2 mg). The relative risk of developing 
advanced AMD (in the other eye in the advanced AMD 
group) was reduced by 25%, and the relative risk of vision 
loss of 3 or more lines was reduced by 19%.11 Since studies 
also found that beta-carotene increased the risk of lung can-
cer in smokers, it was recommended that smokers consider 
omitting beta-carotene from the formulation.12,13 Lutein 
and zeaxanthin, major components in macular pigment, 
may reduce the likelihood of having advanced AMD.14 
Direct evidence of neuro-protection is still lacking but it 
is hypothesized that macular xanthophylls play a role as: 
an important structural molecule within cell membrane, a 
modulator of intra- and extra-cellular reduction-oxidation 
balance; and a short-wavelength light (which is damaging to 
retinal tissues) ﬁ  lter.15 In the same way, omega-3 LCPUAs 
present some structural and functional properties which 
indicate a probable role in visual-sensory process and as a 
protective factor against retinal diseases.16 Indeed, inverse 
relationship of dietary omega-3 LCPUFA intake with 
advanced AMD has been reported in different studies.17,18 
Studies investigating the impact of lutein and omega-3 
fatty acids on the incidence and progression of AMD pro-
vided conﬂ  icted results, though they have been shown to 
be non-toxic to the retina. In response, AREDS 2, which 
started in late 2006, is a multi-center randomized phase III 
study designed to assess the effects of oral supplementation 
of high doses of macular xanthophylls (lutein and zea-
xanthin) and omega-3 LCPUFAs [docosahexaenoic acid 
(DHA) and eicosapentaenoic acid (EPA)] for the treatment 
of AMD and cataract. This study will enroll 4000 subjects 
for a 6-year period.
In addition to the intake of vitamin and minerals 
supplements described by the AREDS study, stopping 
smoking and a healthy diet are strongly recommended.
Treatment of advanced AMD
Exudative AMD
Laser photocoagulation
Thermal laser photocoagulation was ﬁ  rst introduced in an 
attempt to halt the progression of neovascular AMD. The 
Macular Photocoagulation Study (MPS) Group trials assessed 
laser treatment for CNV in three locations: extra-foveal 
(200 μm from the geographic center of the foveal avascular 
zone), juxta-foveal (1–199 μm), and sub-foveal (extending 
directly beneath the geographic center of the foveal avascular 
zone).19–23 In each trial, the control group of untreated 
eyes provided natural history data. Photocoagulation of 
well-demarcated extra-foveal CNV resulted in a signiﬁ  cant Clinical Ophthalmology 2009:3 157
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reduction in the risk of severe vision loss over the ﬁ  rst 
2 years. A recurrence rate of 54% reduced this beneﬁ  t over 
the subsequent 3 years of follow-up. Laser photocoagulation, 
however, did not result in better vision over a longer period 
of time. The relative risk of severe visual loss of 6 or more 
lines among untreated eyes compared to treated eyes was 
1.5 from 6 months through 5 years.19 Photocoagulation of 
well-demarcated juxta-foveal CNV membranes resulted in a 
small overall treatment beneﬁ  t.20–23 The beneﬁ  t was limited 
because of the high rate of persistence and recurrence (80%) 
over a 5-year observation period.24–26 Laser photocoagulation 
of sub-foveal CNV was primarily recommended for lesions 
smaller than two optic discs and with visual acuity below 
20/200. Unfortunately, 82% of treated subjects developed 
visual loss below 20/200 and the laser photocoagulation of 
sub-foveal CNV is no longer recommended as a primary 
treatment option for such lesions.
In summary, while the MPS group trials demonstrated 
an effective therapy for extra-foveal CNV, visual results for 
sub-foveal disease and the high rate of foveal recurrence 
within the ﬁ  rst year were disappointing to patients and to 
their physicians.
Photodynamic therapy using verteporﬁ  n (Visudyne®)
Photodynamic therapy (PDT) with verteporﬁ  n (Visudyne®) 
(vPDT) emerged as a welcome alternative to thermal laser for 
the treatment of CNV. This technique employs intravenous 
administration of a pharmacological photo-sensitizer (eg, 
verteporﬁ  n) followed by physical activation of the substance 
using a 689 nm laser light. Excitation of the photo-sensitizer 
initiates a photochemical reaction involving singlet oxygen 
and reactive oxygen intermediates, which damage endothelial 
cells lining the CNV and can lead to selective occlusion of 
the CNV with less severe effects on the retina and underlying 
choroid. Because a non-thermal light intensity is used to 
induce the photochemical oxidation within the vascular 
endothelium, thermal tissue damage does not theoretically 
occur but vaso-occlusion with concomitant thrombosis 
of the normal choriocapillaris has been documented.27 
Moreover, the thrombotic effect induce an hypoxia which 
locally increase the expression of VEGF.28 The Treatment 
of Age Related Macular Degeneration with Photodynamic 
Therapy (TAP) study found a beneﬁ  t to treatment after 1 and 
2 years.29–31 Subjects with sub-foveal lesions (containing any 
proportion of a classic component) of up to 5400 μm in the 
greatest linear diameter were enrolled in these trials, and 
pre-randomization visual acuity ranged from an approximate 
Snellen equivalent of 20/40 to 20/200. A beneﬁ  t was found 
for the entire population, with 53% of the vPDT-treated 
subjects and 38% of the sham-treated subjects losing fewer 
than 15 letters in visual acuity at 2 years (p  0.001). 
Sub-group analysis by angiographic classiﬁ  cation revealed 
that the beneﬁ  t was largest in predominantly classic lesions 
(in which the area of classic CNV is greater than 50% of the 
entire lesion). In this type of lesion, 59% of vPDT-treated 
eyes compared with 31% of sham-treated eyes lost fewer than 
15 letters. An improvement in vision by 15 letters or more was 
seen in only 9% of treated subjects (including predominantly 
and minimally classic lesions) at the 24 month visit.
The Verteporﬁ  n in Photodynamic therapy (VIP) trial 
enrolled subjects with sub-foveal CNV lesions composed 
of angiographically occult lesion sub-type only, and with a 
presumed recent disease progression (vision loss by at least 
one line, new hemorrhage, or an enlargement of the CNV 
by at least 10% seen by angiography). At 2 years, 45% of 
vPDT-treated eyes compared to 32% of sham-treated eyes lost 
fewer than 15 letters and an improvement in vision by at least 
15 letters was seen in 5% of treated subjects. Loss of 30 letters 
or more was observed in 29% of eyes in the vPDT group versus 
47% of eyes in the placebo group. Sub-group analysis revealed 
that CNV with relatively small size (less than 4 MPS disc 
areas) or relatively low visual acuity (65 letters) had better 
outcomes.32 In this sub-group, 51% of the vPDT-treated eyes 
lost less than 15 letters versus 25% of placebo-treated eyes. 
The beneﬁ  t or stabilization achieved during the ﬁ  rst 2 years 
was often maintained for at least the following 3 years.
The ocular and systemic safety of verteporﬁ  n therapy was 
conﬁ  rmed in the TAP and VIP trials.33 Acute severe visual 
loss (loss of more than 20 letters or 4 lines of vision within 
7 days of verteporﬁ  n therapy) was noted however (0.7% in 
the TAP investigation and 4.9% in the VIP trial) and was 
more often seen in the treatment of large occult lesions with 
better initial visual acuity.34
Participants in the TAP study received on average 
5 treatments over the 2 years and the risk ratio of 
losing 3 or more lines and 6 or more lines of visual acuity 
was 0.77 (95% conﬁ  dence interval 0.69–0.87) and 0.62 (95% 
conﬁ  dence interval 0.50–0.76), respectively.33 The frequency 
of re-treatments decreased from an average of 3.4 in the ﬁ  rst 
year, to 2.2 in the second year, to 0.4 by the fourth year (TAP 
Study Group 2005). An analysis of treatment outcomes by 
lesion size following vPDT from the TAP and VIP studies 
suggested that therapy might reduce the risk of visual loss 
in small, minimally classic lesions.35
In summary, the TAP and VIP studies provided evidence 
of the efficacy and safety of the verteporfin therapy. Clinical Ophthalmology 2009:3 158
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This therapy reduces the risk of further loss in vision by 50%; 
however, an improvement in vision was still a rare event. 
Predominantly classic or purely occult lesions smaller than 
four disc diameters that showed recent progression were 
shown to have better outcomes. Considering the durability 
and need for fewer repeated treatments, in the pre- anti-VEGF 
era, vPDT was an appropriate therapy for sub-foveal CNV, 
new or recurrent, where the classic component is greater than 
50% of the entire lesion (5400 μm; or in an occult CNV 
when the visual acuity is worse than 20/50 or greater than 
20/50 with a lesion size less than a disc diameter).
Anti-VEGF therapies
The VEGF family consists of 6 growth factors (VEGF-A, 
-B, -C, -D, -E, and placental growth factor or PIGF) that 
bind three distinct tyrosine kinase receptors (VEGF-R1, 
VEGF-R2, and VEGF-R3). VEGF-R2 seems to be the 
functional receptor that mediates endothelial cell migration.36 
Different factors appeared to be regulators for VEGF-induced 
angiogenesis, but hypoxia seems to be the most important 
one.37 When activated angiogenesis and vascular permeability 
induced by VEGF are mediated by different pathways.38,39
Multiple studies have suggested that vascular endothelial 
growth factor (VEGF) increases vascular permeability and 
is involved in the pathogenesis of neovascularization in 
human eye disease.40 Current approaches to inhibit VEGF 
involve binding it to a molecule that prevents receptor 
0-ligand interaction, thus incapacitating the effect of VEGF 
on the local environment. Options currently include either a 
full-length recombinant monoclonal antibody (bevacizumab) 
or a highly afﬁ  nitized fragment of the antibody (ranibizumab), 
or a pegylated aptamer (pegabtanib sodium).
Intravitreal injection of pegaptanib (Macugen®): Vascular 
endothelial growth factor 165 has been found to play a major 
role in blood-retinal barrier breakdown and pathological 
intraocular neovascularization.41 Pegaptanib sodium is an 
aptamer composed of ribonucleic acids, which competitively 
blocks VEGF 165 and selectively inhibits angiogenesis and 
leakage.42 Pegaptanib has to be injected into the vitreous 
cavity and re-injections have to be performed every 6 weeks 
as the molecule is rapidly degraded enzymatically by 
intraocular nucleases. Pegaptanib was the ﬁ  rst biological 
molecule to selectively counteract one of the main pathogenic 
stimuli of CNV, while preserving all the physiologic 
structures of the macula.
The efficacy of pegaptanib has been evaluated in a 
randomized, double-masked, multicenter, dose ranging, 
controlled clinical trial (VEGF Inhibition Study in Ocular 
Neovascularization (VISION)).43 A total of 1,186 subjects 
with either classic, minimally classic, or occult membranes 
were included. An intravitreous injection of pegaptanib at 
a dose of 0.3 mg, 1 mg, or 3 mg or a sham injection was 
administered every 6 weeks over a period of 48 weeks. 
Subjects enrolled in the trial were allowed one vPDT 
before the start of the study and any number of vPDT 
treatments throughout the study period at the discretion 
of the investigator. The efﬁ  cacy was demonstrated, for all 
three doses of pegaptanib. In the group given pegaptanib at 
0.3 mg (which was identiﬁ  ed as the lowest safe and effec-
tive dosage), 70% of subjects lost fewer than 15 letters 
of visual acuity, as compared with 55% of subjects in the 
control group (p  0.001). The risk of severe visual loss 
(loss of 30 letters or more) was reduced from 22% in the 
sham-injection group to 10% in the group receiving 0.3 mg of 
pegaptanib (p  0.001). More subjects receiving pegaptanib 
(0.3 mg), as compared to the sham injection, maintained or 
gained visual acuity (33% vs 23%; p = 0.003). The beneﬁ  cial 
effect was seen for all types of neovascularization. Subgroup 
analysis did, however, reveal a slightly larger beneﬁ  t in 
minimally classic lesions, with stabilization in 76% of eyes 
as compared to 54% in the sham group. A 2-year evaluation 
showed that mean visual acuity was maintained in subjects 
continuing with 0.3 mg pegaptanib.44 In order to maintain 
the initial stabilization rates, the injections of pegaptanib 
had to be given throughout the entire 2 years. Twenty-six 
percent of subjects discontinuing treatment after the ﬁ  rst 
year experienced an additional loss of 15 letters versus 
16% in the continued group. Despite treatment, the total size 
of the lesion increased from 3.7 disk diameters at baseline 
to 5.5 at the 2-year follow-up. Six percent of treated eyes 
improved by 3 lines compared to 2% in the sham group. No 
statistical difference was found between the various CNV 
subgroups, however predominantly classic lesions tended to 
do better. Early detection may result in superior visual out-
comes (improvement or stabilization in 76% versus 50% in 
the usual care group).45
The safety proﬁ  le of pegaptanib is favorable at 2 years. 
The most common ocular adverse events were transient, 
mild to moderate in intensity, and related to injection 
preparation and procedure. The injection procedure itself 
can lead to serious ocular adverse events at a rate of 2.1 to 
2.3%/year (endophthalmitis 1.3%/patient, retinal detachment 
0.6%/patient, traumatic cataract 0.6%/patient). In events 
associated with systemic VEGF inhibition, or in severe ocular 
complications when compared to sham treated subjects, there 
was no evidence of an increase in deaths.Clinical Ophthalmology 2009:3 159
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Pegaptanib was approved as the ﬁ  rst anti-VEGF agent 
by the FDA in December 2004 and by the European 
Medicines Agency in January 2006 for all lesion types 
in neovascular AMD. Similar to vPDT monotherapy, the 
beneﬁ  t of a pegaptanib is limited to visual stabilization 
with an overall inability to improve vision. This warrants 
clinicians to examine the risks of intravitreal injections 
versus vPDt.
It is accepted now that intravitreal injections are well 
tolerated and safe when performed according to protocol. 
Though there is an increase in risk of endophthalmitis or 
retinal detachment with intravitreal injections, RPE atrophy 
and photoreceptor loss than can ensue after vPDt is far 
less common with anti-VEGF therapy. In our opinion, 
the beneﬁ  ts of pegaptanib therapy for AMD outweigh the 
risks even though pegaptanib treatment entails intravitreal 
injections every 6 weeks instead of PDT every 12 weeks. 
vPDT is not equally efﬁ  cacious across the lesion subtypes 
and sizes, whereas pegaptanib has effect with all lesion 
subtypes and pharmacotherapy opens up the possibility of 
combination therapy in attacking neovascularization through 
multiple ways.
Intra-vitreal injection of ranibizumab (Lucentis®): 
Ranibizumab is a humanized IgG1 kappa recombinant 
monoclonal antibody fragment that recognizes and binds 
extra-cellular VEGF with high afﬁ  nity. Ranibizumab has the 
ability to bind and inactivate all isoforms of VEGF-A includ-
ing the soluble VEGF fragments (110, 121, and 165) and the 
tissue-bound isoforms 189 and 206.46 Theoretically, ranibi-
zumab, due to its small molecular size, is able to penetrate 
the retina and reach the sub-retinal space and inhibit VEGF. 
Its half life is 2 to 4 days which results in a rapid systemic 
clearance and improved safety.41
A large randomized, multicenter, sham controlled phase 
III study (MARINA study) enrolled 716 subjects with 
minimally classic and occult lesions with evidence of recent 
disease progression. Subjects were randomized to 2 treatment 
groups and 1 sham group. The treatment groups received a 
mean of 22 injections (monthly interval) of ranibizumab 
(0.3 or 0.5 mg) through 24 months. Another prospective 
randomized phase III trial, (ANCHOR), enrolled 423 subjects 
with predominantly classic sub-foveal lesions. This study 
included a monthly injection of either 0.3 or 0.5 mg of 
ranibizumab versus the vPDT treated group. The PIER study 
included 184 subjects with all types of macular exudative 
lesions and evaluated the efﬁ  cacy and safety of ranibizumab, 
which was administered monthly for 3 doses, followed by a 
ﬁ  xed regimen of re-treatments in 3-month intervals.47
The results of the MARINA and ANCHOR studies 
showed that 95% to 96% of the subjects treated with 
ranibizumab (0.5 mg) maintained stable vision within 
3 lines (compared to 62%–64% of sham or PDT group 
treated eyes) at 1 year.48-50 Thirty-four percent to 40% of the 
treated eyes improved by 3 lines of vision (compared to 
6% in the vPDT group and 4% in the sham group). In the 
PIER study, only 13% of the treated subjects experienced an 
improvement in vision, which highlights the importance of an 
individualized re-treatment regimen on a monthly basis. On 
average, subjects treated with Lucentis in the MARINA study 
experienced an improvement from baseline of 6.6 letters at 
2 years compared to a loss of 14.9 letters in the sham group. 
In the ANCHOR study, subjects treated with ranibizumab, on 
average, experienced a 11.3 letter gain from baseline at one 
year compared to a loss of 9.5 letters in the vPDT group. Up 
to 40% of subjects treated with ranibizumab achieved vision 
of 20/40 or better. Patient age, initial visual acuity, lesion 
composition or size did correlate with the functional results 
(visual acuity stabilization or improvement).
The Optical Coherence Tomography Imaging Patients 
with Neovacular AMD Treated with Intra-Ocular Lucentis 
(PrONTO) study evaluated an OCT-guided, variable-dosing 
regimen with intra-vitreal ranibizumab for the treatment of 
subjects with neovascular age-related macular degeneration.51 
This was a prospective open-label study which evaluated 
whether OCT criteria at monthly intervals could be used to 
guide re-treatment with ranibizumab. Patients were enrolled 
within the study regardless of lesion type or previous 
treatment. Patients received intravitreal 0.5-mg ranibizumab 
injections at 0, 1, and 2 months. For the remainder of the 
study, strict criteria were established to determine whether 
the patient received additional intra-vitreal ranibizumab. 
The criteria used were: 1) decrease in acuity of 5 letters and 
any ﬂ  uid by OCT, 2) increase in central macular thickness 
of 100 μm even if visual acuity did not, 3) new hemorrhage, 
4) new classic CNV by fluorescein angiography, and 
5) persistent ﬂ  uid from CNV after last treatment. Forty 
patients were enrolled in the study and received a total 
of 222 injections over the 12 months of follow-up. On 
average, patients gained 9.3 letters at 12 months with 95% of 
patients stable or improved. Only 37.5% of patients needed 
3 or 3 + 1 dose of intra-vitreal ranibizumab to quiesce the 
choroidal neovascular membrane. The mean time to ﬁ  rst 
retreatment was 4.3 months.
Preliminary results from the PrONTO study suggest 
that fewer injections will most likely result in visual acuity 
improvements similar to the results from the phase III trials Clinical Ophthalmology 2009:3 160
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and suggest that less frequent treatment with ranibizumab 
is possible by using a variable dosing regimen with OCT. 
However, the Pronto study does not bring the same level 
evidence that MARINA or ANCHOR brought due to its 
small sample size (40 patients) and limited follow-up and 
treatment recommendations warrant further investigations 
and should be practiced with caution.
Systemic safety was excellent and the death rate did 
not differ between the groups. The frequency of systemic 
thrombo-embolic events (myocardial infarcts), however, 
was slightly higher (not statistically signiﬁ  cant) in subjects 
treated with 0.5 mg of ranibizumab as compared to the 
other treatment groups.52 A phase IIIb SAILOR (Safety 
Assessment of Intra-vitreal Lucentis for Age-Related 
Macular Degeneration) study and the HORIZON trial which 
is a long-term extension study that follow-up subjects who 
participated in the MARINA and ANCHOR trial for 5 years 
are underway to evaluate the safety of ranibizumab. The 
ranibizumab at a dose of 0.5 mg was approved by the FDA 
in June 2006 and by the EMEA in January 2007 for the 
treatment of all lesion types in exudative AMD. An individual 
monthly evaluation allowing treatment on demand when 
leakage or activity of the neovascular lesion is detected is 
recommended.
Intra-vitreal injection of  bevacizumab (Avastin®) – off-label 
therapy: Bevacizumab is a full-length monoclonal antibody 
that binds all iso-forms of VEGF-A. This drug reduces 
angiogenesis and vascular permeability after an intra-vitreal 
injection. Bevacizumab has been FDA approved in the 
treatment of metastatic colorectal carcinoma. Preliminary 
reports have showed promising results regarding the use 
of intra-vitreal injections of bevacizumab in the treatment 
of neovascular AMD. A phase I study (SANA, Systemic 
Avastin for neovascular AMD) in 15 subjects evaluated the 
infusion of 5 mg/kg of bevacizumab in 2-week intervals.53 
A signiﬁ  cant functional and anatomical improvement was 
described at a short-term follow-up (12 weeks). The only 
adverse event identiﬁ  ed was a mild elevation of the systolic 
blood pressure. Short-term uncontrolled retrospective case 
series showed no apparent short-term safety concerns for 
intravitreal bevacizumab injections for CNV, and treated 
eyes had a signiﬁ  cant decrease in macular thickness and 
improvement in visual acuity.54–57 Monthly bevacizumab 
intra-vitreal injections have also been tested for CNV 
which did not respond to other treatments (vPDT and/or 
pegaptanib).58 Seventy-eight percent of eyes experienced an 
anatomical and functional beneﬁ  t after treatment. Ten rabbit 
eyes were injected to evaluate retinal penetration and toxicity 
of bevacizumab, and ERG and PEV responses were similar 
in injected and controlled eyes showing that bevacizumab 
was non-toxic to the retina of rabbits.59
Finally, a randomized, multicenter, clinical trial called 
CATT (Comparison of ARMD Treatments Trials) will 
include 1200 subjects and compare the efﬁ  cacy and safety of 
bevacizumab and ranibizumab. The level of efﬁ  cacy, safety, 
dosage, and re-treatment schedule are unknown until the 
results of the study are revealed. Currently, we may want 
to consider an off-label use of bevacizumab only because 
its cost is less as compared to other available anti-VEGF 
drugs. In summary, this off-label approach appears to have a 
beneﬁ  cial effect in the short-term treatment of all subtypes of 
CNV in AMD, but questions about its safety and long-term 
efﬁ  cacy are still unanswered.
Anti-VEGF therapies are an important breakthrough 
in exudative AMD, but they present issues that need to be 
explained. First, resistance to anti-angiogenic therapy cannot 
be dismissed.40,50,60
Small case series suggest an increased rate of RPE tears 
after an injection though there is no study suggesting that this 
is higher than the rate in untreated patients after one year of 
evolution.61–64 Finally, the long-term systemic safety above 
2 years has not yet been addressed.65,66 It is unlikely, however, 
that we will have better results in terms of safety concerns 
given the reduced life expectancy of patients with AMD and 
concomitant systemic disease (mean 7 years). Most patients 
are likely to die 5 to 10 years after beginning therapy.
Vascular-endothelial growth factor has many essential 
functions, including the formation of collateral vessels 
after ischemia as well as neurotrophic properties. Despite 
intra-vitreous injection, systemic absorption occurs and 
long-term treatment with repeat injections may cause chronic 
inhibition of the VEGF and its associated adverse effects. 
Ongoing safety analysis is being performed in the SAILOR 
trial, the HORIZON trial (extension study of MARINA 
and ANCHOR), as well as the CATT trial. The anti-VEGF 
re-treatment strategy is another question still unanswered. 
A combination of a clinical examination and a qualitative 
OCT to guide anti-VEGF re-treatment, as suggested in the 
PrONTO study, seems to achieve equivalent results when 
compared to giving monthly injections.52
Combined therapies
The pathophysiology of CNV is complex and a combination 
of various therapies that have synergistic modes of action 
may be able to target the multiple components of CNV. 
Theoretically, this can reduce the frequency of re-treatments Clinical Ophthalmology 2009:3 161
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and allow stabilization of the visual improvement above that 
offered by monotherapy alone.
Combination of verteporfin-PDT and steroids: PDT 
with verteporfin produces reactive oxygen species that 
induce closure of the CNV. Unfortunately, there is also a 
release of several potent mediators of the immune system 
(complements, clotting cascades, proteinases, cytokines, and 
growth factors), which can contribute to the re-growth of 
the CNV.67 Corticosteroids are known to exert an inhibitory 
effect on VEGF expression, vascular permeability, and 
inﬂ  ammatory pathway. The complementary action of the 
anti-inﬂ  ammatory and/or anti-angiogenic drugs given in 
combination with vPDT may improve its efﬁ  cacy. Intra-vitreal 
triamcinolone is the drug most tested.68–70 This combination 
(triamcinolone with vPDT) showed an improvement in 
vision in most subjects that was maintained during 2 years 
of follow-up, and re-treatment numbers were lower than that 
expected from monotherapy.71 Furthermore, despite the well 
known side effects of intra-vitreal corticosteroids (cataract, 
elevations in intraocular pressure, and endophthalmitis) the 
preliminary ﬁ  ndings suggest that the combination is safe 
and may be considered as a useful alternative, particularly 
in pseudo-phakic patients.
A new type of steroid, anecortave acetate, which is an 
angiostatic steroid that minimizes the glucocorticoid activity 
(no cataract or elevations in intraocular pressure), is under 
evaluation in combination with vPDT. Preliminary data 
reveal a trend towards more beneﬁ  cial outcomes than with 
single treatment alone.72,73
Verteporfin PDT with anti-angiogenic therapies: 
Treatments for CNV can be directed at either the vascular 
component of the CNV (the new vessels that proliferate and 
leak blood and ﬂ  uid) or the angiogenic components that 
lead to the development of the condition. The combination 
of vPDT which targets the vascular components and the 
anti-VEGF therapy which targets key mediators of the 
angiogenic cascade, may have an additive and synergistic 
effect to reduce the frequency of treatment.74 Moreover, the 
expression of VEGF is increased after vPDT therapy and 
contributes to the re-growth of the CNV.67–75 Different studies 
have evaluated this combination.76
The FOCUS study as well as the PROTECT trial evaluated 
the safety and efﬁ  cacy of ranibizumab in combination with 
vPDT versus vPDT alone. At 1 year, 91% of treated subjects 
had stable vision compared with 68% under vPDT alone. 
The number of vPDT sessions was 2.3 in the combination-
treated subjects versus 3.4 in monotherapy. In the same 
way, 31% of the combination-treated eyes gained at least 
3 lines versus 15% in the vPDT monotherapy group. Although 
ranibizumab treatment increased the risk of serious intra-
ocular inﬂ  ammation, affected subjects, on average, still 
experienced visual acuity beneﬁ  t.77,78 Two non-randomized 
case series evaluated the combination of bevacizumab with 
vPDT. The results suggested that this combination may 
be useful by reducing re-treatment rate and improving 
visual acuity.79,80 The combination therapy may be a cost 
effective alternative for monotherapy by reducing the need 
for re-treatment.
Combination of different anti-VEGF therapies: We 
can inhibit VEGF in various ways. The induction therapy 
with a pan-VEGF inhibitor (ranibizumab or bevacizumab) 
will provide an optimal regression of the CNV and an 
improvement in vision and then the anti-VEGF165 speciﬁ  c 
inhibitor (pegaptanib) may maintain vessel regression with 
a better safety proﬁ  le.
Surgery
Numerous surgical approaches have been developed to 
treat the exudative form of AMD. such as surgical removal 
of sub-foveal CNV, removal of sub-foveal hemorrhage, 
macular translocation, and transplantation of the pigment 
epithelium.
Surgical removal of the CNV: Removal of the CNV 
together with extensive hemorrhage in AMD was first 
described by de Juan in 1988.81 The ﬁ  rst visual results 
of membrane excision were disappointing with visual 
improvement in only 0% to 33% of the cases.82–84 Evaluation 
of the removal of sub-foveal CNV compared with observation 
has been conducted between 1997 and 2003 by the 
Sub-macular Surgery Trials (SST). The SST showed that 
this surgical alternative therapy did not improve vision.85 
A retrospective meta-analysis evaluating 647 cases of 
sub-retinal membrane excision in AMD subjects showed that 
improvement was achieved in about 33% and deterioration 
occurred in 27%. Moreover, the recurrence rate of CNV was 
approximately 25%,86 and the progression of the atrophic 
scar size led to further visual loss. In a patient with recent 
macular hematoma secondary to CNV, different surgical 
options may be considered. The pneumatic displacement of 
the sub-macular hemorrhage with SF6 or C3F8 may allow an 
improvement of the visual acuity.87 More aggressive options 
including three-port vitrectomy, eventual TPA injection, 
hematoma removal, CNV excision, and gas tamponade 
have been proposed with variable functional and anatomical 
results.88 Despite these limited results, there are still some 
indications for sub-macular surgery, such as for patients with Clinical Ophthalmology 2009:3 162
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low preoperative visual acuity due to large hemorrhagic or 
ﬁ  brotic membranes.
Retinal rotation techniques: The ﬁ  rst retinal translocation 
was done by Machemer in 1993.89 The development of a 
partial retinal rotation combined with a scleral shortening has 
been tested for several years.90,91 Because of the very small 
angle of rotation, the high rate of recurrence (approximately 
50%), and the availability of other therapies (vPDT), this tech-
nique is no longer implemented. A complete 360° retinotomy, 
which allows a higher rotation angle of the retina, has been 
proposed in the second eye-affected patients.92 Long-term 
reports have shown favorable visual results with 52% of the 
subjects having one or more lines of improvement, speciﬁ  cally 
reading vision and contrast sensitivity after one year.93–95 
A high rate of PVR (approximately 30% of the cases in inex-
perienced hands and between 8% and 18% in experienced 
hands) limits the use of this surgical technique.96 However, 
retinal rotation with 360° retinotomy may be an alternative in 
a very large CNV, when it does not respond to new therapies 
or when it is associated with large hematomas.
RPE transplantation: The disappointing visual results 
after CNV excision were explained by the simultaneous 
mechanical removal of the RPE layer and the transplantation 
of the RPE seemed to be a logical solution to restore vision. 
Currently, different techniques of autologous transplantation 
of the RPE are under evaluation.97–102 The iris pigment 
epithelial transplantation has been proposed, but this tissue is 
incapable of expressing crucial enzymes of the retinoid visual 
cycle.103 Investigators proposed the use of RPE suspension 
cells harvested through a nasal retinotomy at the beginning of 
the surgery and transplanted in the sub-retinal macular space 
after the excision of the CNV.104,105 A prospective trial was 
conducted with autologous suspension cell transplantation 
after membrane excision compared to membrane excision 
alone. At 12 months, visual improvement of two or more 
lines was achieved in 52.5% of the transplantation group 
(21.5% in the excision alone group), 32.5% remained the 
same, and 15% had a decrease of vision (21.5% in the 
excision alone group). The statistical analysis of far visual 
acuity showed just a trend in favor of the transplanted group, 
but the statistical analysis of the multifocal ERGs showed 
a signiﬁ  cant difference between the two groups, with better 
results in the transplanted group.99 Another transplantation 
technique using a full thickness RPE-choroid sheet has 
been proposed by some researchers with interesting results 
regarding the long-term survival and the revascularization 
of the transplanted tissue.101–106 This technique uses a 
RPE-choroid ﬂ  ap taken in the superior mid-periphery, which 
is directly introduced through the macular retinotomy into the 
sub-retinal space. This particular technique, however, seems 
to be traumatic and presents a high rate of PVR.101
The two main limitations of “one-time” autologous 
transplantation techniques are the graft size and the quality 
of the RPE and the Bruch’s membrane. Culturing prior to 
transplantation may offer the potential to at least partially 
inﬂ  uence or reverse aging and the lipofuscin load per cell 
might be reduced by dilution during cell division. This 
“rejuvenation” process may also be combined with a potential 
gene defect correction.107 Unfortunately, the right surgical 
technique (with a prosthetic Bruch’s membrane) and a viable 
method of culturing are not yet available. RPE-like cells 
generated from embryonic stem cells, neural stem cells, or 
bone marrow derived cells, however, may represent the future 
of the RPE transplantation in AMD.108
End stage bilateral AMD (atrophic or exudative): 
low vision rehabilitation
At the end stages of exudative or atrophic macular 
degeneration, when previously described treatments have 
been unsuccessful, patients may become severely visually 
impaired. This may cause significant disability, with 
difﬁ  culties in reading and daily activities, all of which 
may impact on quality of life.109,110 In such situations, low 
vision rehabilitation should be offered to the patient.111 
In low vision rehabilitation, people are taught to use their 
remaining vision more effectively. Using a variety of visual 
aids may allow the patient to become more independent. 
Most of the time, low vision rehabilitation provides high 
patient satisfaction with functional and subjective improve-
ments.112–115 The rehabilitation of a visually impaired 
individual may involve a variety of treatment modalities 
including prescription eyewear, optical devices, electronic 
aids, adaptive computer software, glare control, modiﬁ  cation 
of the patient’s environment, counseling and education of the 
patient and family, skills training, independent living aids, 
occupational therapy, mental health intervention, orientation 
and mobility training, and driving rehabilitation.
In summary, low vision rehabilitation has to be offered to 
each patient with bilateral advanced AMD complaining of a loss 
of vision. Low vision aid may be started simultaneously with 
other therapies before the onset of signiﬁ  cant disability.
Recent advances in the treatment of CNV due to AMD 
have led to major improvements in anatomical and functional 
results. The prognosis of exudative AMD has completely 
changed in the last few years. Since the cost of these recent 
therapies has dramatically increased, the expenses for the Clinical Ophthalmology 2009:3 163
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individual patient has also risen.116 A value-based medicine 
cost utility analysis was performed on different interventions 
for neovascular AMD to assess the value that each confers 
to the patient.117 Laser therapy confers 4.4% of value gain, 
pegaptanib a 5.9% gain, vPDT an 8.1% gain and ranibizumab 
a 15% gain, which is considered quite high. To put it into 
perspective, HMG-CoA reductase inhibitors (statins) given 
for hyperlipidemia confer only a 6.3% value gain.
Conclusion
Over the last 20 years, a multitude of clinical trials have 
evaluated the efﬁ  cacy of various treatment modalities for 
neovascular AMD. Thermal laser successfully prevented the 
proliferation of CNV; however, visual loss and recurrences 
impaired the treatment beneﬁ  t. Using non-thermal laser energy 
through vPDT appeared as a healthy alternative, but again, 
it was unsatisfying to both the patient and treating clinician 
given the inability to improve vision in a majority of patients. 
As we begin to better understand the pathophysiology 
of CNV and the role of VEGF in its development and 
persistence, newer pharmacologic interventions have led to 
previously unattainable results regarding improvements in 
vision. But again, we are faced with a new problem. We are 
far better at initiating the medication than we are at stopping it. 
Just as oncologists treat cancer with various chemotherapies 
that act in concert, we also are beginning to experiment 
with combination therapy in an attempt to discontinue the 
cycle of repetitive treatment. Although it appears promising, 
retrospective and small prospective studies are no substitute 
for large, randomized, controlled trials. As our understanding 
of the disease continues to grow at the molecular level, 
investigators are simultaneously exploring other treatment 
venues that may offer a more long-term solution, such as the 
inhibition of gene expression and signal transduction. In short, 
we are making headways in the treatment of neovascular 
AMD, but there is still much to be explored and learned, 
particularly in its prevention.
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